Art. -Nr.: HY-13595

Chrysophanol

(Synonyms: Chrysophanic acid)

6 Cited Publications

Kundenbewertung

Based on 6 publication(s) in Google Scholar

Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and mTOR/p70S6K.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.66%
CAS. Nr.: 481-74-3
Formel: C₁₅H₁₀O₄
Molecular Weight:254.24

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Chrysophanol Chemical Structure

CAS. Nr.: 481-74-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (6)
Lösungsmittel & Löslichkeit
- In Vitro
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and mTOR/p70S6K.

IC₅₀ & Target^[1]

EGFR

Alle EGFR Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	>60 μM Compound: 1	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 24326280]
A549	IC₅₀	5.7 μM Compound: 26	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by sulforhodamine B assay	[PMID: 33691166]
Calu-1	IC₅₀	>100 μM Compound: 6	Inhibition of human Calu1 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of human Calu1 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]
DU-145	GI₅₀	>62.5 μg/mL Compound: 3	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 18163590]
HCT-116	IC₅₀	47.4 μM Compound: 1	Cytotoxicity against MDR1 Pgp under-expressing human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against MDR1 Pgp under-expressing human HCT116 cells after 24 hrs by MTT assay	[PMID: 17949858]
HeLa	IC₅₀	>100 μM Compound: 6	Inhibition of human HeLa cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of human HeLa cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]
HepG2	IC₅₀	64.4 μM Compound: 1	Cytotoxicity against MDR1 Pgp overexpressing human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against MDR1 Pgp overexpressing human HepG2 cells after 24 hrs by MTT assay	[PMID: 17949858]
HepG2 2.2.15	IC₅₀	300 μg/mL Compound: 52	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV DNA production Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV DNA production	[PMID: 24549242]
HepG2 2.2.15	IC₅₀	300 μg/mL Compound: 52	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion	[PMID: 24549242]
HepG2 2.2.15	IC₅₀	300 μg/mL Compound: 52	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV surface antigen secretion Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV surface antigen secretion	[PMID: 24549242]
HT-29	GI₅₀	>62.5 μg/mL Compound: 3	Cytotoxicity against human HT29 cells Cytotoxicity against human HT29 cells	[PMID: 18163590]
HUVEC	ED₅₀	>5 μg/mL Compound: chrysophanol	Cytotoxicity against HUVEC Cytotoxicity against HUVEC	[PMID: 15043409]
K562	GI₅₀	>62.5 μg/mL Compound: 3	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 18163590]
K562	IC₅₀	>100 μM Compound: 6	Inhibition of human K562 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of human K562 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]
KB	EC₅₀	>20 μM Compound: 11	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 17552563]
KB	ED₅₀	5.68 μg/mL Compound: 1	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	10.1021/np50085a021
LNCaP	ED₅₀	>5 μg/mL Compound: chrysophanol	Cytotoxicity against human LNCAP cells Cytotoxicity against human LNCAP cells	[PMID: 15043409]
Lu1	ED₅₀	>5 μg/mL Compound: chrysophanol	Cytotoxicity against human Lu1 cells Cytotoxicity against human Lu1 cells	[PMID: 15043409]
M14	GI₅₀	>62.5 μg/mL Compound: 3	Cytotoxicity against human M14 cells Cytotoxicity against human M14 cells	[PMID: 18163590]
MCF7	ED₅₀	>5 μg/mL Compound: chrysophanol	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 15043409]
MCF7	GI₅₀	>62.5 μg/mL Compound: 3	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 18163590]
ME-180	GI₅₀	>62.5 μg/mL Compound: 3	Cytotoxicity against human ME180 cells Cytotoxicity against human ME180 cells	[PMID: 18163590]
NCI-H157	IC₅₀	2.7 μM Compound: 26	Antiproliferative activity against human NCI-H157 cells assessed as reduction in cell viability measured after 72 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H157 cells assessed as reduction in cell viability measured after 72 hrs by sulforhodamine B assay	[PMID: 33691166]
NCI-H460	GI₅₀	>62.5 μg/mL Compound: 3	Cytotoxicity against human H460 cells Cytotoxicity against human H460 cells	[PMID: 18163590]
NIH3T3	GI₅₀	>62.5 μg/mL Compound: 3	Cytotoxicity against BALB/c mouse 3T3 cells Cytotoxicity against BALB/c mouse 3T3 cells	[PMID: 18163590]
PC-3	GI₅₀	>62.5 μg/mL Compound: 3	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 18163590]
PLC-PRF-5	ED₅₀	3.23 μg/mL Compound: 1	Cytotoxicity against human PLC/PRF/5 cells Cytotoxicity against human PLC/PRF/5 cells	10.1021/np50085a021
Raji	IC₅₀	>100 μM Compound: 6	Inhibition of human Raji cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of human Raji cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]
Vero	GI₅₀	>62.5 μg/mL Compound: 3	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 18163590]
Vero	IC₅₀	>100 μM Compound: 6	Inhibition of african green monkey Vero cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of african green monkey Vero cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]
WISH	IC₅₀	>100 μM Compound: 6	Inhibition of human WISH cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of human WISH cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]

In Vitro

Chrysophanol (Chrysophanic Acid) blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway. Chrysophanol, a natural anthraquinone, has anticancer activity in EGFR-overexpressing SNU-C5 human colon cancer cells. Chrysophanol treatment in SNU-C5 cells inhibits EGF-induced phosphorylation of EGFR and suppresses activation of downstream signaling molecules, such as AKT, extracellular signal-regulated kinase (ERK) and the mammalian target of Rapamycin (mTOR)/ribosomal protein S6 kinase (p70S6K). Chrysophanol (80 and 120 μM) significantly blocks cell proliferation when combined with the mTOR inhibitor, Rapamycin. Chrysophanol inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and mTOR/p70S6K, and significantly blocks cell proliferation. Chrysophanol dose dependently decreases CCK-8 and the viability of EGFR-overexpressing SNU-C5 cells. Chrysophanol treatment dose-dependently decreases EGF induced phosphorylation of EGFR at Tyr1068. Chrysophanol (80 and 120 μM) reduces the phosphorylation levels of mTOR at Ser2448. Chrysophanol (80 and 120 μM) also decreases the phosphorylation levels of p70S6K at Thr389. Chrysophanol inhibits EGF-induced EGFR activation and suppresses activation of the downstream signaling molecules, AKT and mTOR/p70S6K^[1]. Chrysophanol (CA) inhibits lipid accumulation in 3T3-L1 adipocytes. Chrysophanol down-regulates adipogenic factors in 3T3-L1 adipocytes. Chrysophanol induces thermogenic factors in primary cultured brown adipocytes. Chrysophanol suppresses adipogenesis and induces thermogenesis via activation of AMPK pathway^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Chrysophanol (CA) improves HFD-induced obesity in C57BL/6 Mice. The in vivo performance of Chrysophanol is performed in male C57BL/6J mice to determine the efficacy of administered Chrysophanol. Mice fed the HFD gained significantly more weight than those fed the standard diet mice. On the other hand, weight gain of Chrysophanol group is significantly less than with the untreated HFD. Mice in the HFD-group gained 23.92 ± 1.74 g of weight, while those in the Chrysophanol group gained 16.72±2 g of weight after 16 weeks^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 481-74-3
Appearance Solid
Molecular Weight 254.24
Formel C₁₅H₁₀O₄
Color Yellow to orange
SMILES

O=C1C2=C(C=CC=C2O)C(C3=CC(C)=CC(O)=C13)=O
Synonyms

Chrysophanic acid
Structure Classification
- Quinones
- Anthraquinones
- Phenols
- Polyphenols
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (6)

All Bio/Physico-chemical AssayCell Imaging/StainingIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Acta Pharm Sin B

Chrysophanol protects against doxorubicin-induced cardiotoxicity by suppressing cellular PARylation. [Abstract]

2019 Jul;9(4):782-793. PMID: 31384538

Chrysophanol purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2019 Jul;9(4):782-793. [Abstract]

To further assess the role of Chrysophanol in DOX-induced mitochondrial injury, we treated cells with Chrysophanol and DOX, results clearly showed that Chrysophanol suppressed DOX induced mitochondrial membrane depolarization and the mitochondria swelling.

Chrysophanol purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2019 Jul;9(4):782-793. [Abstract]

Chrysophanol (10-20 μmol/L) protected against DOX-induced cardiac apoptosis and mitochondrial damage in control cells while ectopic expression of PARP1 effectively blocked this Chrysophanol’s cardioprotection.

Chrysophanol purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2019 Jul;9(4):782-793. [Abstract]

To explore the effects of CHR or 3AB (a PARP1 inhibitor) on the cardiac function of DOX-induced rats, the different doses of Chrysophanol (Low: 5 mg/kg/day; Medium: 20 mg/kg/day; High: 40 mg/kg/day) or 3AB (40 mg/kg/day) were intragastrically or intraperitoneally treated to SD rats one time every day for 7 days before DOX administration. Control group were treated with the vehicle in an equal volume of CMC-Na. Results showed that the hearts from DOX-treated rats were distinctly smaller than those from control rats.

Chrysophanol purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2019 Jul;9(4):782-793. [Abstract]

To explore the effects of CHR or 3AB (a PARP1 inhibitor) on the cardiac function of DOX-induced rats, the different doses of Chrysophanol (Low: 5 mg/kg/day; Medium: 20 mg/kg/day; High: 40 mg/kg/day) or 3AB (40 mg/kg/day) were intragastrically or intraperitoneally treated to SD rats one time every day for 7 days before DOX administration. Control group were treated with the vehicle in an equal volume of CMC-Na. The results showed that significant myocardial fibrosis and inflammatory cell infiltration were observed by Sirius red and HE staining.
Chem Eng J

2025 Jul 15.

Chrysophanol purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2025 Jul 15.

Hoechst fluorescence intensity (λex = 350 nm) of tFNA-Chrysophanol by mixing tFNA and Chrysophanol in different ratios (tFNA:Chr = 1:50–250).

Chrysophanol purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2025 Jul 15.

Zeta potential of tFNA and tFNA-Chrysophanol measured by DLS.
Phytother Res

Chrysophanol Attenuates Glucocorticoid-Induced Osteoporosis by Targeting the E74-Like Factor 5/Osteoglycin-Regulated PI3K/AKT/mTOR Signaling Axis: An In Vitro and In Vivo Study. [Abstract]

2026 Apr;40(4):2143-2165. PMID: 41657040
Molecules

In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei. [Abstract]

2020 Apr 23;25(8):1980. PMID: 32340370
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Research Square Preprint

2021 Nov.

Lösungsmittel & Löslichkeit

In Vitro:

DMF : 4 mg/mL (15.73 mM; Need ultrasonic)

DMSO : 2 mg/mL (7.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9333 mL

19.6665 mL

39.3329 mL

5 mM

0.7867 mL

3.9333 mL

7.8666 mL

10 mM

0.3933 mL

1.9666 mL

3.9333 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Protokoll

Cell Assay^[1]

The cells are seeded at 5×10³ cells/mL in 96-well microplates and allowed to attach for 24 h. Chrysophanol (20, 50, 80 and 120 μM) is added to the medium at various concentrations up to 120 μM and for different durations. After treatment, cell cytotoxicity and/or proliferation is assessed by a Cell Counting Kit-8 (CCK-8). Briefly, highly water-soluble tetrazolium salt, WST-8, produces an orange colored water-soluble product, formazan. The amount of formazan dye generated by dehydrogenases in cells is directly proportional to the number of living cells.CCK-8 (10 μL) is added to each well and incubated for 3 h at 37°C, then cell proliferation and cytotoxicity are assessed by measuring the absorbance at 450 nm using a microplate reader.Three replicated wells are used for each experimental condition^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
Male 4-week-old C57BL/6J mice are maintained for 1 week prior to experiments. Mice are maintained on a 12-h light/dark cycle in a pathogen-free animal facility, provided with laboratory diet and water ad libitum. To induce obesity, the mice are fed a HFD with 60% kcal% fat. Control group (C) are fed a commercial standard chow diet. HFD group (HFD) mice are fed with HFD only. HFD plus CA group (CA) Mice are fed with HFD for 4 weeks before administration of Chrysophanol (5 mg/kg/day). The mice are divided into three groups (n = 5) that are fed chow diet, HFD, and HFD plus Chrysophanol for 16 weeks. Body weight and food intake are measured three times per week.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lee MS, et al. Chrysophanic acid blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway. Phytother Res. 2011 Jun;25(6):833-7. [Content Brief]

[2]. Lim H, et al. Chrysophanic Acid Suppresses Adipogenesis and Induces Thermogenesis by Activating AMP-Activated Protein Kinase Alpha In vivo and In vitro. Front Pharmacol. 2016 Dec 8;7:476. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / DMF	1 mM	3.9333 mL	19.6665 mL	39.3329 mL	98.3323 mL
DMSO / DMF	5 mM	0.7867 mL	3.9333 mL	7.8666 mL	19.6665 mL
DMF	10 mM	0.3933 mL	1.9666 mL	3.9333 mL	9.8332 mL
DMF	15 mM	0.2622 mL	1.3111 mL	2.6222 mL	6.5555 mL

Keywords

Chrysophanol

6 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Chrysophanol

Natural Product Library Plus

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Chrysophanol

Alle EGFR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Chrysophanol

Natural Product Library Plus

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Chrysophanol

Alle EGFR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Chrysophanol Related Classifications

HY-13595 Related Classifications